Add group to favorites
Back to post list
Send new message to group Search:
Post Subject:
Strontium For Osteoporosis
Re: Strontium For Osteoporosis
"BoneLady" <srsupporter@gmail,com > wrote in message
news:aef6fbc6-32dc-43f8-9245-934c7277a855@79g2000hsk.googlegroups,com ...
On May 1, 3:18 am, "trigonometry1...@gmail,com |"
<trigonometry1...@gmail,com > wrote:
> Strontium ranelate reduces the risk of vertebral fractures
> in patients with osteopenia.
> Seeman E, Devogelaer JP, Lorenc R, Spector T,
> Brixen K, Balogh A, Stucki G, Reginster JY.
>
> Austin Health, University of
> Melbourne, Australia. e...@unimelb.edu.au
>
> Many fractures occur in women with moderate fracture
> risk caused by osteopenia. Strontium ranelate was
> studied in 1431 postmenopausal women with osteopenia.
> Vertebral fracture risk reduction of 41-59% was
> shown depending on the site and fracture status at
> baseline. This is the first report of antivertebral
> fracture efficacy in women with vertebral osteopenia.
>
> INTRODUCTION:
> Women withosteoporosisare at high risk
> for fracture. However, more than one half of all
> fractures in the community originate from the larger
> population at more moderate risk of fracture caused by
> osteopenia. Despite this, evidence for antifracture
> efficacy in these persons is limited. The aim of this
> study was to determine whether strontium ranelate,
> a new drug that reduces fracture risk in women with o
> steoporosis, is also effective in women with osteopenia.
>
> MATERIALS AND METHODS:
> Data from the SpinalOsteoporosisTherapeutic Intervention
> study (SOTI; n = 1649) and the TReatment Of PeripheralOSteoporosis(TROPOS;
> n = 5091) were pooled to evaluate
> the antivertebral fracture efficacy of strontium ranelate
> in women with lumbar spine (LS) osteopenia with any BMD
> value at the femoral neck (FN; N = 1166) and in 265
> women with osteopenia at both sites (intention-to-treat analysis).
> The women were randomized to strontium ranelate 2 g/d orally
> or placebo for 3 yr.
>
> RESULTS:
> No group differences were present
> in baseline characteristics that may influence fracture
> outcome independent of therapy. In women with LS osteopenia,
> treatment reduced the risk of vertebral fracture by 41%
> (RR = 0.59; 95% CI, 0.43-0.82), by
> 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients
> with no prevalent fractures, and
> by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients
> with prevalent fractures. In women with osteopenia at
> both sites, treatment reduced the risk of fracture
> by 52% (RR = 0.48; 95% CI, 0.24-0.96).
>
> CONCLUSIONS:
> Strontium ranelate safely reduces the risk of vertebral
> fractures in women with osteopenia with or without a prevalent
> fracture.
>
> PMID: 17997711
Thank you for the informative article on strontium ranelate, a
prescription drug not available in the U.S.A. Strontium citrate is
available without a prescription. Since it is the strontium that is
incorporated into the bone matrix, any easily assimilable strontium
salt should work just as well in preventing bone fractures.Please
visit my non-commercial blog on strontium for osteoporosis and
osteopenia at http :// strontiumforbones.blogspot,com /
BoneLady
===============================
Non-commercial, eh??
Yet you fail, afaict, to mention *any other* non-strontium modality--pretty
narrow focus for an old lady w/ osteo. lol.
Well, at least your citrate, discounted, seems reasonable in price, but the
mere--and likely artificial--inhibition of bone resorption is likely not the
be-all and end-all, either, as normal resorption/deposition is an
equilibrium process.
Osteo indicates something else is amiss in the process--see below.
The resorption of bone is likely the shedding of skin, digestive mucosal
cells, etc. Ie, resorption/deposition keeps bone "fresh"--as long as the
deposition part occurs!
You omit exercise, calcium, magnesium, vit D, and a host of other trace
minerals associated w/ bone, boron being just one.
And strategies for the above, such as divided doses for all nutrients, ESP
calcium, which is 1. not easily absorbed to begin with, and 2. whose
absorption can quite decrease with age.
For someone with osteo, I would recommend something on the order of 200-250
mg four to six times a day.
High amounts of phosphoric acid, as in Coke, supposedly wreak havoc with
bone density, and greatly increase Ca requirements.
Studies have also shown that there is no greater nutritional bull than
"calcium absorbability" schemes.
Turns out that the plain, cheap Calcium carbonate is absorbed as well or
better than chelates, and all the other crap.
This is because most calcium compounds are cleaved right in the stomach, so
it ultimately it is only ionic calcium reaching the gut, no matter how it is
compounded.
Overly-complexing calcium, such as in strong chelates and carboxylic acids
(a common food moeity), actually hinders absorption.
Exercise should probably not be percussive, such as in running, but not this
namby-pamby useless stuff either.
As much weight, range of motion, both in extension and compression, as the
old body will safely allow.
Uphill walking, weights, hanging, calisthenics, **isometrics**, and perhaps
an experimental brief jog or two, as tolerated, on very soft surfaces--sand,
dirt, etc, in good sneakers.
Perhaps as a precursor to attempts at jogging would be mild "bouncing" to
very slight jumping, as in jumping rope. This is actually fairly low
impact, if the knees are kept bent, and low impact if the feet don't leave
the floor. Burns calories, too.
Isometrics are a powerful method, intrinsically employed by yoga, QiChong,
and less so in the more interesting Tai Chi.
Simply standing on one leg, with eyes closed if possible, for 15+ seconds,
is surprisingly difficult, even for me --a Dr. Roizen recommendation as a
test of aging, but a great exercise in its own right, both neural and
muscular.
Many people will have to steady themselves with a chair or wall, but the
goal is to do it freestanding.
Mild dips of the knee (very shallow one-legged kneebends) will substantially
load the leg, hips. The deep one-legged kneebends is a very advanced
technique among martial artists.
Shallow or deep, this is a super-exercise for *anyone*.
There are a number of isometric websites, and numerous techniques.
Gadgets are unnecessary, and in fact, the two best isometric aids are a
broomstick and a rope. Limb against limb are super as well.
Older people, unsteady or insecure, should certainly guard against falls,
have padding/cushions/matts around, and something or someone to hold on to.
4" foam is great (upholstery shops). Older people can start by simply
shifting the weight from one foot to another, before outright raising one
leg.
Walking in place, lifting each knee as high as is safely tolerable, is not a
bad start either.
Roizen talked about the importance of learning how to fall in older people.
4" foam is good for this also, and the mere act of rolling onto one's back
and then climbing back up into a standing position multiple times is no
trivial thing, even for un-old people. 10 reps of that will leave anyone
starting to breathe heavy.
--
DT
"BoneLady" <srsupporter@gmail,com > wrote in message
news:aef6fbc6-32dc-43f8-9245-934c7277a855@79g2000hsk.googlegroups,com ...
On May 1, 3:18 am, "trigonometry1...@gmail,com |"
<trigonometry1...@gmail,com > wrote:
> Strontium ranelate reduces the risk of vertebral fractures
> in patients with osteopenia.
> Seeman E, Devogelaer JP, Lorenc R, Spector T,
> Brixen K, Balogh A, Stucki G, Reginster JY.
>
> Austin Health, University of
> Melbourne, Australia. e...@unimelb.edu.au
>
> Many fractures occur in women with moderate fracture
> risk caused by osteopenia. Strontium ranelate was
> studied in 1431 postmenopausal women with osteopenia.
> Vertebral fracture risk reduction of 41-59% was
> shown depending on the site and fracture status at
> baseline. This is the first report of antivertebral
> fracture efficacy in women with vertebral osteopenia.
>
> INTRODUCTION:
> Women withosteoporosisare at high risk
> for fracture. However, more than one half of all
> fractures in the community originate from the larger
> population at more moderate risk of fracture caused by
> osteopenia. Despite this, evidence for antifracture
> efficacy in these persons is limited. The aim of this
> study was to determine whether strontium ranelate,
> a new drug that reduces fracture risk in women with o
> steoporosis, is also effective in women with osteopenia.
>
> MATERIALS AND METHODS:
> Data from the SpinalOsteoporosisTherapeutic Intervention
> study (SOTI; n = 1649) and the TReatment Of PeripheralOSteoporosis(TROPOS;
> n = 5091) were pooled to evaluate
> the antivertebral fracture efficacy of strontium ranelate
> in women with lumbar spine (LS) osteopenia with any BMD
> value at the femoral neck (FN; N = 1166) and in 265
> women with osteopenia at both sites (intention-to-treat analysis).
> The women were randomized to strontium ranelate 2 g/d orally
> or placebo for 3 yr.
>
> RESULTS:
> No group differences were present
> in baseline characteristics that may influence fracture
> outcome independent of therapy. In women with LS osteopenia,
> treatment reduced the risk of vertebral fracture by 41%
> (RR = 0.59; 95% CI, 0.43-0.82), by
> 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients
> with no prevalent fractures, and
> by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients
> with prevalent fractures. In women with osteopenia at
> both sites, treatment reduced the risk of fracture
> by 52% (RR = 0.48; 95% CI, 0.24-0.96).
>
> CONCLUSIONS:
> Strontium ranelate safely reduces the risk of vertebral
> fractures in women with osteopenia with or without a prevalent
> fracture.
>
> PMID: 17997711
Thank you for the informative article on strontium ranelate, a
prescription drug not available in the U.S.A. Strontium citrate is
available without a prescription. Since it is the strontium that is
incorporated into the bone matrix, any easily assimilable strontium
salt should work just as well in preventing bone fractures.Please
visit my non-commercial blog on strontium for osteoporosis and
osteopenia at http :// strontiumforbones.blogspot,com /
BoneLady
===============================
Non-commercial, eh??
Yet you fail, afaict, to mention *any other* non-strontium modality--pretty
narrow focus for an old lady w/ osteo. lol.
Well, at least your citrate, discounted, seems reasonable in price, but the
mere--and likely artificial--inhibition of bone resorption is likely not the
be-all and end-all, either, as normal resorption/deposition is an
equilibrium process.
Osteo indicates something else is amiss in the process--see below.
The resorption of bone is likely the shedding of skin, digestive mucosal
cells, etc. Ie, resorption/deposition keeps bone "fresh"--as long as the
deposition part occurs!
You omit exercise, calcium, magnesium, vit D, and a host of other trace
minerals associated w/ bone, boron being just one.
And strategies for the above, such as divided doses for all nutrients, ESP
calcium, which is 1. not easily absorbed to begin with, and 2. whose
absorption can quite decrease with age.
For someone with osteo, I would recommend something on the order of 200-250
mg four to six times a day.
High amounts of phosphoric acid, as in Coke, supposedly wreak havoc with
bone density, and greatly increase Ca requirements.
Studies have also shown that there is no greater nutritional bull than
"calcium absorbability" schemes.
Turns out that the plain, cheap Calcium carbonate is absorbed as well or
better than chelates, and all the other crap.
This is because most calcium compounds are cleaved right in the stomach, so
it ultimately it is only ionic calcium reaching the gut, no matter how it is
compounded.
Overly-complexing calcium, such as in strong chelates and carboxylic acids
(a common food moeity), actually hinders absorption.
Exercise should probably not be percussive, such as in running, but not this
namby-pamby useless stuff either.
As much weight, range of motion, both in extension and compression, as the
old body will safely allow.
Uphill walking, weights, hanging, calisthenics, **isometrics**, and perhaps
an experimental brief jog or two, as tolerated, on very soft surfaces--sand,
dirt, etc, in good sneakers.
Perhaps as a precursor to attempts at jogging would be mild "bouncing" to
very slight jumping, as in jumping rope. This is actually fairly low
impact, if the knees are kept bent, and low impact if the feet don't leave
the floor. Burns calories, too.
Isometrics are a powerful method, intrinsically employed by yoga, QiChong,
and less so in the more interesting Tai Chi.
Simply standing on one leg, with eyes closed if possible, for 15+ seconds,
is surprisingly difficult, even for me --a Dr. Roizen recommendation as a
test of aging, but a great exercise in its own right, both neural and
muscular.
Many people will have to steady themselves with a chair or wall, but the
goal is to do it freestanding.
Mild dips of the knee (very shallow one-legged kneebends) will substantially
load the leg, hips. The deep one-legged kneebends is a very advanced
technique among martial artists.
Shallow or deep, this is a super-exercise for *anyone*.
There are a number of isometric websites, and numerous techniques.
Gadgets are unnecessary, and in fact, the two best isometric aids are a
broomstick and a rope. Limb against limb are super as well.
Older people, unsteady or insecure, should certainly guard against falls,
have padding/cushions/matts around, and something or someone to hold on to.
4" foam is great (upholstery shops). Older people can start by simply
shifting the weight from one foot to another, before outright raising one
leg.
Walking in place, lifting each knee as high as is safely tolerable, is not a
bad start either.
Roizen talked about the importance of learning how to fall in older people.
4" foam is good for this also, and the mere act of rolling onto one's back
and then climbing back up into a standing position multiple times is no
trivial thing, even for un-old people. 10 reps of that will leave anyone
starting to breathe heavy.
--
DT
Re: Strontium For Osteoporosis
Strontium ranelate reduces the risk of vertebral fractures
in patients with osteopenia.
Seeman E, Devogelaer JP, Lorenc R, Spector T,
Brixen K, Balogh A, Stucki G, Reginster JY.
Austin Health, University of
Melbourne, Australia. egos@unimelb.edu.au
Many fractures occur in women with moderate fracture
risk caused by osteopenia. Strontium ranelate was
studied in 1431 postmenopausal women with osteopenia.
Vertebral fracture risk reduction of 41-59% was
shown depending on the site and fracture status at
baseline. This is the first report of antivertebral
fracture efficacy in women with vertebral osteopenia.
INTRODUCTION:
Women with osteoporosis are at high risk
for fracture. However, more than one half of all
fractures in the community originate from the larger
population at more moderate risk of fracture caused by
osteopenia. Despite this, evidence for antifracture
efficacy in these persons is limited. The aim of this
study was to determine whether strontium ranelate,
a new drug that reduces fracture risk in women with o
steoporosis, is also effective in women with osteopenia.
MATERIALS AND METHODS:
Data from the Spinal Osteoporosis Therapeutic Intervention
study (SOTI; n = 1649) and the TReatment Of Peripheral
OSteoporosis (TROPOS; n = 5091) were pooled to evaluate
the antivertebral fracture efficacy of strontium ranelate
in women with lumbar spine (LS) osteopenia with any BMD
value at the femoral neck (FN; N = 1166) and in 265
women with osteopenia at both sites (intention-to-treat analysis).
The women were randomized to strontium ranelate 2 g/d orally
or placebo for 3 yr.
RESULTS:
No group differences were present
in baseline characteristics that may influence fracture
outcome independent of therapy. In women with LS osteopenia,
treatment reduced the risk of vertebral fracture by 41%
(RR = 0.59; 95% CI, 0.43-0.82), by
59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients
with no prevalent fractures, and
by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients
with prevalent fractures. In women with osteopenia at
both sites, treatment reduced the risk of fracture
by 52% (RR = 0.48; 95% CI, 0.24-0.96).
CONCLUSIONS:
Strontium ranelate safely reduces the risk of vertebral
fractures in women with osteopenia with or without a prevalent
fracture.
PMID: 17997711
Strontium ranelate reduces the risk of vertebral fractures
in patients with osteopenia.
Seeman E, Devogelaer JP, Lorenc R, Spector T,
Brixen K, Balogh A, Stucki G, Reginster JY.
Austin Health, University of
Melbourne, Australia. egos@unimelb.edu.au
Many fractures occur in women with moderate fracture
risk caused by osteopenia. Strontium ranelate was
studied in 1431 postmenopausal women with osteopenia.
Vertebral fracture risk reduction of 41-59% was
shown depending on the site and fracture status at
baseline. This is the first report of antivertebral
fracture efficacy in women with vertebral osteopenia.
INTRODUCTION:
Women with osteoporosis are at high risk
for fracture. However, more than one half of all
fractures in the community originate from the larger
population at more moderate risk of fracture caused by
osteopenia. Despite this, evidence for antifracture
efficacy in these persons is limited. The aim of this
study was to determine whether strontium ranelate,
a new drug that reduces fracture risk in women with o
steoporosis, is also effective in women with osteopenia.
MATERIALS AND METHODS:
Data from the Spinal Osteoporosis Therapeutic Intervention
study (SOTI; n = 1649) and the TReatment Of Peripheral
OSteoporosis (TROPOS; n = 5091) were pooled to evaluate
the antivertebral fracture efficacy of strontium ranelate
in women with lumbar spine (LS) osteopenia with any BMD
value at the femoral neck (FN; N = 1166) and in 265
women with osteopenia at both sites (intention-to-treat analysis).
The women were randomized to strontium ranelate 2 g/d orally
or placebo for 3 yr.
RESULTS:
No group differences were present
in baseline characteristics that may influence fracture
outcome independent of therapy. In women with LS osteopenia,
treatment reduced the risk of vertebral fracture by 41%
(RR = 0.59; 95% CI, 0.43-0.82), by
59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients
with no prevalent fractures, and
by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients
with prevalent fractures. In women with osteopenia at
both sites, treatment reduced the risk of fracture
by 52% (RR = 0.48; 95% CI, 0.24-0.96).
CONCLUSIONS:
Strontium ranelate safely reduces the risk of vertebral
fractures in women with osteopenia with or without a prevalent
fracture.
PMID: 17997711
Re: Strontium For Osteoporosis
Sorry about the multiple postings, Google was behaving oddly last
night and it didn't seem to be accepting my postings.
More on the topic.
1: Aust Fam Physician. 2007 Aug;36(8):631-2.
Strontium ranelate--does it affect the management of postmenopausal
osteoporosis?
Winzenberg T, Powell S, Jones G.
Menzies Research Institute, University of Tasmania.
tania.winzenberg@utas.edu.au
This series of articles facilitated by the Cochrane
Musculoskeletal Group (CMSG) aims to place the findings
of recent Cochrane musculoskeletal reviews in a
context immediately relevant to general practitioners.
This article considers whether the availability of
strontium ranelate affects the management of
postmenopausal osteoporosis.
PMID: 17676187 [PubMed - indexed for MEDLINE]
Full article is available by way of a PUBMED link to site with no
charge for the article.
===================================
1: J Bone Miner Res. 2005 Sep;20(9):1569-78.
Epub 2005 Apr 27.
Long-term strontium ranelate administration in
monkeys preserves characteristics of bone mineral
crystals and degree of mineralization of bone.
Farlay D, Boivin G, Panczer G, Lalande A, Meunier PJ.
Laboratoire d'Histodynamique Osseuse,
Faculté de Médecine R. Laennec, Université
C. Bernard-Lyon 1, Lyon, France.
In monkeys, long-term strontium ranelate administration
results in a dose-dependent bone strontium uptake
(mainly into newly formed bone) that
preserves the degree of mineralization of bone
and the bone mineral at the crystal level,
showing its safety at bone mineral level.
INTRODUCTION:
Strontium ranelate simultaneously increases bone formation
and decreases bone resorption, leading to prevention of
bone loss and increase in bone mass and bone strength in
normal and ovariectomized rats. This study investigated
the interactions of stable strontium (Sr) with bone
mineral in monkeys after long-term strontium
ranelate treatment and after a period of treatment withdrawal.
MATERIALS AND METHODS:
Iliac bone was obtained from untreated monkeys, monkeys at
the end of a 52-week strontium ranelate administration
(200, 500, 1250 mg/kg/day orally), and in parallel
groups 10 weeks after the end of strontium ranelate
administration (same three doses; n = 3-7).
Sr uptake and distribution in bone mineral were
quantified by X-ray microanalysis, changes at the
crystal level by X-ray diffraction, and the degree of
mineralization of bone (DMB) by quantitative
microradiography.
RESULTS:
After strontium ranelate administration, dose-dependent
Sr uptake occurred into cortical and cancellous bone,
with higher content (1.6 times) in new than in old bone.
This Sr uptake decreased (50%) 10 weeks after treatment
withdrawal; the decrease occurred almost exclusively in new
bone. At the end of strontium ranelate treatment and after
its withdrawal, a preservation of crystal characteristics
was observed, suggesting that Sr was only
faintly linked to crystals by ionic substitution and of DMB.
CONCLUSIONS:
These results show the absence of a deleterious
effect of long-term strontium ranelate
treatment on bone mineralization, confirming
the histomorphometric observations made in postmenopausal
osteoporotic women treated with strontium ranelate.
PMID: 16059629 [PubMed - indexed for MEDLINE]
Related Links
The mineralization of bone tissue: a forgotten dimension in
osteoporosis
research. [Osteoporos Int. 2003] PMID:12730799
Strontium distribution and interactions with bone mineral in
monkey iliac bone
after strontium salt (S 12911) administration. [J Bone Miner Res.
1996]
PMID:8864905
Strontium ranelate improves bone resistance by increasing bone
mass and improving
architecture in intact female rats. [J Bone Miner Res. 2004] PMID:
15537445
Strontium ranelate in osteoporosis. [Curr Pharm Des. 2002] PMID:
12171530
Strontium ranelate inhibits bone resorption while maintaining bone
formation in
alveolar bone in monkeys (Macaca fascicularis). [Bone. 2001] PMID:
11502480
=====================
Final note:
Other salts other than ranelate of strontium worked in rodents.
Sorry about the multiple postings, Google was behaving oddly last
night and it didn't seem to be accepting my postings.
More on the topic.
1: Aust Fam Physician. 2007 Aug;36(8):631-2.
Strontium ranelate--does it affect the management of postmenopausal
osteoporosis?
Winzenberg T, Powell S, Jones G.
Menzies Research Institute, University of Tasmania.
tania.winzenberg@utas.edu.au
This series of articles facilitated by the Cochrane
Musculoskeletal Group (CMSG) aims to place the findings
of recent Cochrane musculoskeletal reviews in a
context immediately relevant to general practitioners.
This article considers whether the availability of
strontium ranelate affects the management of
postmenopausal osteoporosis.
PMID: 17676187 [PubMed - indexed for MEDLINE]
Full article is available by way of a PUBMED link to site with no
charge for the article.
===================================
1: J Bone Miner Res. 2005 Sep;20(9):1569-78.
Epub 2005 Apr 27.
Long-term strontium ranelate administration in
monkeys preserves characteristics of bone mineral
crystals and degree of mineralization of bone.
Farlay D, Boivin G, Panczer G, Lalande A, Meunier PJ.
Laboratoire d'Histodynamique Osseuse,
Faculté de Médecine R. Laennec, Université
C. Bernard-Lyon 1, Lyon, France.
In monkeys, long-term strontium ranelate administration
results in a dose-dependent bone strontium uptake
(mainly into newly formed bone) that
preserves the degree of mineralization of bone
and the bone mineral at the crystal level,
showing its safety at bone mineral level.
INTRODUCTION:
Strontium ranelate simultaneously increases bone formation
and decreases bone resorption, leading to prevention of
bone loss and increase in bone mass and bone strength in
normal and ovariectomized rats. This study investigated
the interactions of stable strontium (Sr) with bone
mineral in monkeys after long-term strontium
ranelate treatment and after a period of treatment withdrawal.
MATERIALS AND METHODS:
Iliac bone was obtained from untreated monkeys, monkeys at
the end of a 52-week strontium ranelate administration
(200, 500, 1250 mg/kg/day orally), and in parallel
groups 10 weeks after the end of strontium ranelate
administration (same three doses; n = 3-7).
Sr uptake and distribution in bone mineral were
quantified by X-ray microanalysis, changes at the
crystal level by X-ray diffraction, and the degree of
mineralization of bone (DMB) by quantitative
microradiography.
RESULTS:
After strontium ranelate administration, dose-dependent
Sr uptake occurred into cortical and cancellous bone,
with higher content (1.6 times) in new than in old bone.
This Sr uptake decreased (50%) 10 weeks after treatment
withdrawal; the decrease occurred almost exclusively in new
bone. At the end of strontium ranelate treatment and after
its withdrawal, a preservation of crystal characteristics
was observed, suggesting that Sr was only
faintly linked to crystals by ionic substitution and of DMB.
CONCLUSIONS:
These results show the absence of a deleterious
effect of long-term strontium ranelate
treatment on bone mineralization, confirming
the histomorphometric observations made in postmenopausal
osteoporotic women treated with strontium ranelate.
PMID: 16059629 [PubMed - indexed for MEDLINE]
Related Links
The mineralization of bone tissue: a forgotten dimension in
osteoporosis
research. [Osteoporos Int. 2003] PMID:12730799
Strontium distribution and interactions with bone mineral in
monkey iliac bone
after strontium salt (S 12911) administration. [J Bone Miner Res.
1996]
PMID:8864905
Strontium ranelate improves bone resistance by increasing bone
mass and improving
architecture in intact female rats. [J Bone Miner Res. 2004] PMID:
15537445
Strontium ranelate in osteoporosis. [Curr Pharm Des. 2002] PMID:
12171530
Strontium ranelate inhibits bone resorption while maintaining bone
formation in
alveolar bone in monkeys (Macaca fascicularis). [Bone. 2001] PMID:
11502480
=====================
Final note:
Other salts other than ranelate of strontium worked in rodents.
